Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Abstract: Amyotrophic lateral sclerosis (ALS) is a multisystem neurodegenerative ... networks engaged prior to motor output is essential for understanding the motor pathophysiology in ALS. We recorded ...

Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other ...

Ancient Viral DNA in the Human Genome Linked to Multiple Sclerosis and Amyotrophic Lateral Sclerosis Oct. 21, 2024 — New research has revealed a connection between ancient viral DNA embedded in ...

The number of ALS cases in the U.S. is expected to increase by over 10% by 2030, as compared with 2022 prevalence rates, per ...

Dr Maria outlined the following goals for the series: Objectives specific to the tuberous sclerosis complex symposium included description of diagnostic strategies, review of pathogenesis ...

JAMA 275:194-198, 1996. Over the last several years, a number of advances have been made in understanding the pathogenesis and treatment of pneumonia, as well as in the development of effective ...

A Phase 1 trial testing RAG-17, a potential ALS therapy for people carrying SOD1 mutations, has dosed its first participant.